Free Trial

Repligen (RGEN) 10K Form and Latest SEC Filings 2026

Repligen logo
$122.31 0.00 (0.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$122.38 +0.08 (+0.06%)
As of 07:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Repligen SEC Filings & Recent Activity

Repligen (NASDAQ:RGEN) has submitted 457+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Repligen's financial statements. The most recent filing was a Form 4 submitted on May 18, 2026.

Form 4
REPLIGEN CORP Reports Ownership Change on May. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Repligen Files Current Report on May. 15, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Repligen Files Annual Report on Feb. 26, 2026

The 10-K contains Repligen's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Repligen SEC Filing History

Browse Repligen's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/18/2026 3:05 PM
BARTHELEMY NICOLAS (1283576) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
MUIR GLENN P (1181190) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
DAWES KAREN A (1261506) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
Pax Margaret (1999772) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
EGLINTON MANNER CARRIE (1696776) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
Mhatre Rohin (1798735) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
Konstantinov Konstantin (1774649) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:05 PM
Madaus Martin D (1310268) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2026 7:09 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2026 1:39 PM
Douglass Brian Robb (2104618) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 1:48 PM
MUIR GLENN P (1181190) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 6:06 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/22/2026 12:26 PM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 11:44 AM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2026 10:37 AM
Repligen (730272) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/23/2026 10:51 AM
Garland Jason K (1754555) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 10:53 AM
Bylund James (1849642) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 10:53 AM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 11:00 AM
KURIYEL RALF (1733143) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 12:25 PM
KURIYEL RALF (1733143) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 12:28 PM
Bylund James (1849642) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 1:02 PM
Bylund James (1849642) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 12:30 PM
KURIYEL RALF (1733143) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 12:33 PM
Garland Jason K (1754555) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 12:38 PM
Hunt Anthony (1606030) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 12:39 PM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 11:48 AM
Douglass Brian Robb (2104618) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 3:03 PM
Repligen (730272) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/24/2026 6:33 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 9:26 AM
PRICE T ROWE ASSOCIATES INC /MD/ (80255) Filed by
Repligen (730272) Subject
Form SCHEDULE 13G/A
02/13/2026 2:58 PM
Repligen (730272) Subject
Roy T. Eddleman Living Trust (2111539) Filed by
Form SCHEDULE 13G/A
02/05/2026 12:36 PM
FMR LLC (315066) Filed by
Repligen (730272) Subject
Form SCHEDULE 13G
01/12/2026 3:32 PM
Douglass Brian Robb (2104618) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:30 PM
Douglass Brian Robb (2104618) Reporting
Repligen (730272) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/06/2026 6:32 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/18/2025 3:30 PM
DAWES KAREN A (1261506) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 3:30 PM
MUIR GLENN P (1181190) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 3:30 PM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 11:06 AM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 3:30 PM
Bylund James (1849642) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 3:10 PM
Bylund James (1849642) Reporting
Repligen (730272) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Important SpaceX PREDICTION (Ad)

The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian says investors are about to miss the real opportunity. A little-known FCC filing Elon quietly submitted earlier this year has caught Morgan Stanley's attention — and they estimate it could be worth $40 trillion. That's larger than Tesla, xAI, Starlink, X, Neuralink, and SpaceX combined.tc pixel

Click here for the full breakdown before the IPO date arrives
11/12/2025 3:37 PM
Hunt Anthony (1606030) Reporting
Repligen (730272) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/04/2025 3:07 PM
Repligen (730272) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/28/2025 6:33 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/06/2025 9:59 AM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/26/2025 1:30 PM
Garland Jason K (1754555) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2025 1:55 PM
Hunt Anthony (1606030) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2025 3:22 PM
Hunt Anthony (1606030) Reporting
Repligen (730272) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 12:35 PM
PRICE T ROWE ASSOCIATES INC /MD/ (80255) Filed by
Repligen (730272) Subject
Form SCHEDULE 13G/A
09/04/2025 11:47 AM
Hughes Violetta (1991429) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 9:55 AM
Loeillot Olivier (1995525) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 8:44 AM
Hughes Violetta (1991429) Reporting
Repligen (730272) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/02/2025 7:55 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2025 11:47 AM
Madaus Martin D (1310268) Reporting
Repligen (730272) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2025 3:46 PM
Repligen (730272) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/29/2025 6:31 AM
Repligen (730272) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Repligen SEC Filings - Frequently Asked Questions

Repligen (RGEN) has submitted 457+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Repligen's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Repligen's financial statements page.

The most recent filing was a Form 4 submitted on May 18, 2026. This was an insider ownership change filed by 4 - REPLIGEN CORP (0000730272) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:RGEN) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners